FocalTherics Reports Q2 2026 Revenue of $13.2M; Net Loss $14.5M
FocalTherics (FOCL) reported Q2 2026 continuing-operations revenue of $13.2M, up 39% year over year, with gross profit of $7.3M and 55.6% gross margin. Net loss was $14.5M, or $0.39 per share. Cash was $21.5M at June 30, 2026. The company also announced an underwritten public offering for about $40M expected to close Aug. 14, 2026.
How this was made
The 30-second read
Why it matters
For trading, the key new inputs are (1) the reported Q2 continuing-ops revenue and gross margin, (2) the still-large net loss, and (3) the announced underwritten public offering with an expected Aug. 14 close that can affect valuation via dilution and funding expectations.
Market read
This is a company-specific earnings and financing update for a medical device platform, combining growth metrics with a near-term capital raise catalyst.
What to watch
Traders should focus on the shift to classifying ESWL and Distribution as discontinued operations, since it can change comparability and future reported profitability versus prior periods.
Background
FocalTherics’ Q2 2026 results separate continuing operations (HIFU business, Focal One platform) from ESWL and Distribution, which are treated as discontinued operations.
Ticker impact
FocalTherics reported Q2 2026 continuing-ops revenue of $13.2M (+39% YoY) and announced an underwritten public offering expected to close Aug. 14.
Likely choppy reaction: initial relief from revenue/gross margin improvement, offset by dilution risk from the announced offering and ongoing losses.
The article contains primary financial results plus a specific, time-bound capital raise (expected close Aug. 14). Net loss remains large, so traders will weigh growth momentum against dilution and cash runway (cash $21.5M at June 30).
Market effects
Signals continued commercialization traction for HIFU systems (Focal One) in medical devices, but highlights ongoing profitability challenges typical for early commercialization.
Limited direct regional read-through; Europe launch of an endometriosis program may support sentiment for European procedure demand.
Global installed-base growth (184 systems) suggests international adoption, which can influence peer sentiment in procedural oncology/gynecology device platforms.
Counterpoint
The revenue and gross margin improvement could be driven by mix or one-time factors, and the offering may be necessary because cash burn remains high, not because growth is self-funding.
Key entities
- companyFocalTherics
Reported Q2 2026 continuing-operations revenue of $13.2M, net loss of $14.5M, and announced an underwritten public offering expected to close Aug. 14, 2026.
